Kennedy Giulia C 4/A
4/A · VERACYTE, INC. · Filed Mar 9, 2022
Insider Transaction Report
Form 4/AAmended
VERACYTE, INC.VCYT
Kennedy Giulia C
Chief Scientific & Med Officer
Transactions
- Sale
Common Stock
2022-03-04$26.49/sh−100$2,649→ 61,361 total - Exercise/Conversion
Common Stock
2022-03-04$5.98/sh+4,407$26,354→ 84,394 total - Award
Common Stock
2022-03-03+42,412→ 79,987 total - Sale
Common Stock
2022-03-04$24.91/sh−17,089$425,697→ 67,305 total - Sale
Common Stock
2022-03-04$25.70/sh−5,844$150,189→ 61,461 total - Award
Stock Option (right to buy)
2022-03-03+77,287→ 77,287 totalExercise: $26.02Exp: 2032-03-03→ Common Stock (77,287 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-03-04−4,407→ 0 totalExercise: $5.98Exp: 2028-03-01→ Common Stock (4,407 underlying)
Footnotes (6)
- [F1]Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.
- [F2]The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.
- [F3]Represents weighted average sales price. Sale prices for the transactions range from $24.40 to $25.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- [F4]Represents weighted average sales price. Sale prices for the transactions range from $25.41 to $26.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- [F5]The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
- [F6]The option is fully vested.